LEVOCETIRIZINE DIHYDROCHLORIDE - Generic Drug Details

What are the generic sources for levocetirizine dihydrochloride and what is the scope of freedom to operate?

Levocetirizine dihydrochloride is the generic ingredient in four branded drugs marketed by Apotex, Chartwell Molecular, Padagis Us, Taro, Hetero Labs Ltd Iii, Chattem Sanofi, Dr Reddys, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules, Ipca Labs Ltd, Macleods Pharms Ltd, Micro Labs Ltd India, Perrigo R And D, Sankalp Lifecare, Sciegen Pharms, Sun Pharm, Sun Pharm Inds Ltd, Synthon Bv, Teva Pharms, and Us Antibiotics, and is included in twenty-eight NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Levocetirizine dihydrochloride has thirty patent family members in twenty-four countries.

There are eleven drug master file entries for levocetirizine dihydrochloride. Fifty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LEVOCETIRIZINE DIHYDROCHLORIDE

International Patents:	30
US Patents:	1
Tradenames:	4
Applicants:	21
NDAs:	28
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	51
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	70
Patent Applications:	555
Drug Prices:	Drug price trends for LEVOCETIRIZINE DIHYDROCHLORIDE
Drug Sales Revenues:	Drug sales revenues for LEVOCETIRIZINE DIHYDROCHLORIDE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVOCETIRIZINE DIHYDROCHLORIDE
What excipients (inactive ingredients) are in LEVOCETIRIZINE DIHYDROCHLORIDE?	LEVOCETIRIZINE DIHYDROCHLORIDE excipients list
DailyMed Link:	LEVOCETIRIZINE DIHYDROCHLORIDE at DailyMed

See drug prices for LEVOCETIRIZINE DIHYDROCHLORIDE

See drug sales revenues for LEVOCETIRIZINE DIHYDROCHLORIDE

Recent Clinical Trials for LEVOCETIRIZINE DIHYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Derma Techno Pakistan	NA
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	PHASE2
Sheikh Zayed Medical College	PHASE2

See all LEVOCETIRIZINE DIHYDROCHLORIDE clinical trials

Generic filers with tentative approvals for LEVOCETIRIZINE DIHYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		2.5MG/5ML	SOLUTION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LEVOCETIRIZINE DIHYDROCHLORIDE

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for LEVOCETIRIZINE DIHYDROCHLORIDE

R06AE	Piperazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

R06AE	Piperazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for LEVOCETIRIZINE DIHYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYZAL	Oral Solution	levocetirizine dihydrochloride	0.5 mg/mL	022157	1	2009-01-14
XYZAL	Tablets	levocetirizine dihydrochloride	5 mg	022064	1	2007-12-17

US Patents and Regulatory Information for LEVOCETIRIZINE DIHYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sciegen Pharms	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	TABLET;ORAL	203646-001	Sep 9, 2014	AB	RX	No	No
Macleods Pharms Ltd	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	TABLET;ORAL	205564-001	Jan 11, 2016	AB	RX	No	No
Apotex	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	TABLET;ORAL	203027-001	Feb 13, 2015		DISCN	No	No

Expired US Patents for LEVOCETIRIZINE DIHYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	SOLUTION;ORAL	022157-001	Jan 28, 2008
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	TABLET;ORAL	022064-001	May 25, 2007
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	TABLET;ORAL	022064-001	May 25, 2007

International Patents for LEVOCETIRIZINE DIHYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
South Korea	101185612
Spain	2332462
World Intellectual Property Organization (WIPO)	2006005507

Supplementary Protection Certificates for LEVOCETIRIZINE DIHYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103

Market Dynamics and Financial Trajectory for Levocetirizine Dihydrochloride

Last updated: March 5, 2026

What defines the current market landscape for Levocetirizine Dihydrochloride?

Levocetirizine Dihydrochloride is a second-generation antihistamine used primarily for allergic rhinitis and chronic urticaria. The global market size was valued at approximately USD 1.15 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2030, reaching around USD 2 billion by 2030 (Grand View Research, 2023).

How is the market segmented by application?

• Allergic Rhinitis: Represents 65% of the market, with high prevalence in North America and Europe.
• Chronic Urticaria: Accounts for 35%, with rising demand in Asia-Pacific markets.

What are the major drivers influencing growth?

• Increasing prevalence of allergic conditions: The WHO reports that allergic rhinitis affects up to 30% of the global population.
• Rising geriatric population: Older adults have higher incidences of allergies.
• Patent expirations and generic entry: Several patented formulations are expiring, increasing market accessibility.
• Regulatory approvals: Expanded indications and flexible dosing enhance market penetration.

Who are the primary market players?

• Sanofi: Market leader with multiple formulations.
• Teva Pharmaceuticals: Focuses on generics.
• Mylan: Offers cost-competitive options.
• Dr. Reddy’s Laboratories: Expanding in emerging markets.

How does the pipeline appear?

Numerous pharmaceutical companies are developing novel formulations, including:

• Extended-release variants.
• Combination therapies with other antihistamines or nasal steroids.
• Injectable forms for rapid onset.

What are the key regulatory considerations?

• Approval pathways vary by region, with the US FDA requiring bioequivalence data for generics.
• Europe’s EMA emphasizes safety profiles consistent with post-marketing surveillance.
• Emerging markets often have expedited review processes for drugs meeting unmet needs.

What are the financial implications?

• Pricing Strategies: Price points vary globally; North America commands premium prices, while emerging markets lean toward lower-cost generics.
• Revenue Streams: Branded products generate higher margins but face generic competition; generics sustain volume growth.
• R&D Investment: Companies are allocating 8-12% of revenue into research for new delivery platforms and expanded indications.
• Market Risks: Patent cliff, regulatory hurdles, and competition from alternative treatments (e.g., leukotriene receptor antagonists).

How have recent patent expirations impacted the market?

• The last major patent for an Levocetirizine product expired in 2019.
• The entry of generics has led to a price decline of up to 60% in pharmacies.
• Brand consolidation has increased, with top players strengthening positions before patent losses.

What is the projected financial trajectory?

• The market is forecasted to grow steadily into the early 2030s.
• Price erosion from generics will compress profit margins for branded drugs.
• Investment in differentiated product lines may balance pricing pressures.

How does regional variation impact revenue?

Region	Market Share (2022)	Growth Rate (2023-2030)	Key Factors
North America	40%	5.5%	High prevalence, brand loyalty
Europe	20%	6.2%	Regulatory stability, aging population
Asia-Pacific	25%	7.5%	Rising awareness, population growth
Rest of World	15%	5.0%	Emerging markets, cost sensitivity

What are the barriers to market expansion?

• Patent challenges.
• Pricing and reimbursement policies.
• Supply chain disruptions.
• Competition from emerging antihistamines and alternative therapies.

Key Takeaways

• The global Levocetirizine Dihydrochloride market will expand mainly driven by increased allergy prevalence and demographic shifts.
• Patent expirations lead to price competition and lower margins for branded products.
• Emerging markets offer growth opportunities, but require navigating regulatory and cost barriers.
• Innovation in formulations and combination therapies remains a focus for sustainment.
• Regional differences influence revenue potential and strategic planning.

FAQs

1. When do top patents for Levocetirizine expire?
Most key patents expired between 2018 and 2020, leading to a surge in generic availability.

2. Which markets are expected to grow fastest?
Asia-Pacific is projected to have the highest CAGR (~7.5%) due to rising allergy diagnostics and treatment awareness.

3. What competitive strategies are companies adopting?
Focusing on R&D for extended-release formulations, expanding indications, and entering emerging markets through partnerships.

4. How will pricing trends evolve?
Pricing will decline in markets with patent expirations but remain stable or premium in regions where branded drugs have market exclusivity.

5. What are the regulatory hurdles for new formulations?
Demonstrating bioequivalence, safety, and efficacy; approval timelines vary by jurisdiction but generally extend 12–24 months.

---

References

[1] Grand View Research. (2023). Levocetirizine Market Size & Trends.
[2] WHO. (2022). Allergic Rhinitis Factsheet.
[3] EMA. (2022). Guidance on Generic Pharmaceuticals.